Entera
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hadassah Bio Park Fl 5, Jerusalem, Jerus...Phone Number
+97225327151Website
www.enterabio.comRevenue
-Stock Symbol
ENTXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Entera
Entera is a leader in the development of orally delivered macromolecules, including peptides and other therapeutic proteins. The Company focuses on significant unmet medical needs where a mini daily tablet form of a peptide treatment or replacement therapy holds the potential to transform the standard of care. The Company’s most advanced product candidates, EB613 for the treatment of high risk, post-menopausal osteoporosis and EB612 for the treatment of hypoparathyroidism, are in clinical development.Explore more
Entera Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Entera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Entera launches new products
Funding: Get notified immidiatlly once Entera has new funding data
Check out if Entera is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Entera has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Entera
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Entera, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Entera recently announced quarterly report
Click to see if Entera had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Entera is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Entera is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Entera.
Entera financials insights
Gather financial insights about Entera, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$7.5M
2026
Stock/Share Issuance
$275M
Entera Tech Stack
A closer look at the technologies used by Entera
Most Recent Scoops
Earnings
Earnings, Finance
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Entera News & Media
Entera Announces Second Quarter 2026 Financial Results and Business Updates
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with OsteoporosisEntera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase 2 clinical trial of EB613 (oral PTH(1-34) tablet) has been selected for two presentations including the Plenary Poster Presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9–12, 2026, at the John B. HynesEntera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference, details as below.Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides, in connection with its oversubscribed $275 million private placement financing. The financing is expected to extend Entera...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Entera
Sign Up For FreeTo access detailed company insights
Entera is a leader in the development of orally delivered macromolecules, including peptides and other therapeutic proteins. The Company focuses on significant unmet medical needs where a mini daily tablet form of a peptide treatment or replacement therapy holds the potential to transform the standard of care. The Company’s most advanced product ca... Read More
